Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma
Michela Maur(Azienda Ospedaliero-Universitaria di Modena), PierFranco Conte(University of Padua), Massimo Dominici(University of Modena and Reggio Emilia), Antonino Maiorana(University of Modena and Reggio Emilia), Annalisa Fontana(Azienda Ospedaliero-Universitaria di Modena), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Paolo Corradini(Gruppo di Ricerca Geriatrica), Angela Toss(University of Modena and Reggio Emilia)
Cited by 21
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718